Beyondspring Inc's Comment on Sales, Marketing and Customers
The company does not currently have internal sales, marketing, or distribution capabilities. In China, it holds an exclusive commercialization and co-development agreement with Hengrui for Plinabulin, targeting the treatment of non-small cell lung cancer (NSCLC), prevention of chemotherapy-induced neutropenia (CIN), and any additional approved indications. Plinabulin was designated as a 2017 National Science and Technology Major Project in China and is included in the National Drug Priority Review List, which may facilitate its inclusion in the National Insurance System pending approval and pricing negotiations. In the U.S. and other global markets, the company intends to seek co-development and commercialization partners to advance Plinabulin across multiple cancer indications. The company faces challenges in establishing or maintaining collaborative arrangements and may have limited control over third-party marketing efforts. Developing an internal commercial organization would require substantial resources, and there is competition in recruiting marketing and sales personnel.
Revolutionizing NSCLC Treatment: Plinabulin/Docetaxel Combination Offers Enhanced Survival and Quality of LifeAt the forefront of oncological research, BeyondSpring Pharmaceuticals has unveiled promising final data from its DUBLIN-3 Phase 3 clinical study, presented at the ESMO Congress 2024. This pivotal study is set to redefine treatment paradigms for patients grappling with second-line and third-line non-small cell lung cancer (NSCLC) who exhibit wild-type epidermal growth factor receptor (EGFR) status. The findings herald a significant breakthrough in therapeutic approaches, indicating that the combination of plinabulin and docetaxel not only offers superior efficacy compared to docetaxel alone but also...
BeyondSpring Inc., a clinical-stage global biopharmaceutical company specializing in innovative cancer therapies, recently held a virtual Research and Development (RandD) Day to highlight its latest breakthroughs. The event focused on discussing the potential of Plinabulin, the Company s lead asset, as a dendritic cell (DC) maturation agent in combination with other drugs to address unmet medical needs in specific cancer indications. Additionally, BeyondSpring provided updates on SEED Therapeutics, a subsidiary focused on target protein degradation (TPD) platform for molecular glue drug discovery. These recent developments hold significant implications for the company s future trajectory.Plinabulin s Potenti...
Beyondspring Inc’s Comment on Sales, Marketing and Customers
The company does not currently have internal sales, marketing, or distribution capabilities. In China, it holds an exclusive commercialization and co-development agreement with Hengrui for Plinabulin, targeting the treatment of non-small cell lung cancer (NSCLC), prevention of chemotherapy-induced neutropenia (CIN), and any additional approved indications. Plinabulin was designated as a 2017 National Science and Technology Major Project in China and is included in the National Drug Priority Review List, which may facilitate its inclusion in the National Insurance System pending approval and pricing negotiations. In the U.S. and other global markets, the company intends to seek co-development and commercialization partners to advance Plinabulin across multiple cancer indications. The company faces challenges in establishing or maintaining collaborative arrangements and may have limited control over third-party marketing efforts. Developing an internal commercial organization would require substantial resources, and there is competition in recruiting marketing and sales personnel.
Sources:
Beyondspring Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Beyondspring Inc’s corporate clients.
For your research, we’ve provided 9 tables on Beyondspring Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
